NCT00533923View on ClinicalTrials.gov

Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 31, 2002

Primary Completion Date

January 31, 2007

Study Completion Date

January 31, 2007

Conditions
AMLALLCLLMyelodysplastic SyndromeNon-Hodgkin's LymphomaHodgkin's LymphomaMultiple MyelomaAplastic AnemiaMyeloproliferative Disorder
Interventions
DRUG

Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF

intravenous

Trial Locations (1)

02215

Beth Israel Deaconess Medical Center, Boston

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Beth Israel Deaconess Medical Center

OTHER